跳至主要内容
临床试验/NCT02490709
NCT02490709Unknown2 期

Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial

National Cancer Center, Korea2 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2015年4月最近更新:
适应症

试验速览

阶段
2 期
入组人数
86
试验地点
2
主要终点
3-year disease free survival

研究概览

简要总结

The purpose of this study is evaluation of the safety and the efficacy of transanal local excision in patients with cT3 rectal cancer which was downstaged into ycT0-1 after neoadjuvant chemoradiotherapy.

详细描述

This study is a prospective multicenter single-arm phase II clinical trial. Rectal cancer patients with cT3 stage will receive neoadjuvant chemoradiotherapy, and be evaluated the response of the tumor in 6 to 10 weeks after completion of neoadjuvant chemoradiotherapy. For those who have good response (ycT0-1) will underwent transanal local excision under the patients' agree.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age: more than 20 years
  • biopsy-proven adenocarcinoma of the rectum
  • clinical staging, cT3NxM0
  • Rectal cancer located 8 cm from the anal verge
  • Restaging in 6-10 weeks after completion of neoadjuvant chemoradiotherapy, ycT0-1N0M0
  • ECOG performance status 2 or less

排除标准

  • Synchronous colon cancer or other malignancy
  • Obstructing rectal cancer
  • Pregnant or breast-feeding
  • Receiving any other study agents
  • History of prior colorectal cancer or inflammatory bowel disease
  • Hereditary colorectal cancer (FAP, HNPCC)

结局指标

主要结局

3-year disease free survival

时间窗: 1-5 years

Death or recurrence as an event

次要结局

  • Complete response rate(1-5 years)
  • Overall survival rate(1-5 years)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Jae Hwan Oh

Director, Hospital

National Cancer Center, Korea

研究点 (2)

Loading locations...

相似试验